TARGET AUDIENCE
The primary target audience for this content is the hematology care team, including physicians, nurse practitioners, pharmacists, PAs, and social workers.

PROGRAM OVERVIEW
The goal of this education is to improve the hemophilia care team’s abilities to integrate new and emerging hemophilia therapies into clinical practice.

Upon completion of this activity, the learners should be able to:

• Assess how emerging rebalancing treatments impact the individualization of treatment for patients with hemophilia
• Compare the clinical profiles of emerging rebalancing therapies for hemophilia
• Outline strategies for preparing treatment teams and centers for emerging rebalancing therapies in hemophilia

FACULTY
Amy Shapiro, MD
Hematology
Pediatric Hematologist-Oncologist
Medical Director
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana
United States of America

Stacy Croteau, MD, MMS
Medical Director, Boston Bleeding Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Boston Children’s Hospital
Boston, Massachusetts
United States of America

Emily Bisson, APRN, CPNP
Hematology/Oncology
Instructor in Medicine, Geisel School of Medicine
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
United States of America

PLANNING COMMITTEE
Amy Shapiro, MD
Hematology
Pediatric Hematologist-Oncologist
Medical Director
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana
United States of America

Sanjay Ahuja, MD
Pediatric Hematologist-Oncologist
Chief Medical and Informatics Officer
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana
United States of America

Stacy Croteau, MD, MMS
Medical Director, Boston Bleeding Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Boston Children’s Hospital
Boston, Massachusetts
United States of America

Emily Bisson, APRN, CPNP
Hematology/Oncology
Instructor in Medicine, Geisel School of Medicine
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
United States of America

In support of improving patient care, this activity has been planned and implemented by The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Physicians: The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The France Foundation designates this activity for 1.0 contact hour.

Physician Assistants: The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until February 26, 2026. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists: This knowledge-based activity, UAN JA0007204-9999-25-034-H01-P, qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

Social Workers: As a Jointly Accredited Organization, The France Foundation is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 continuing education credit.

All other health care professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all of their educational programs.

Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF and ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This education is supported by independent, educational grants from Novo Nordisk and Pfizer.

The France Foundation and ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, ISTH, and the commercial supporter(s) assume no liability for the information herein.

Copyright © 2025 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at www.francefoundation.com/privacy.